Swipe om te navigeren naar een ander artikel
Irritable bowel syndrome with diarrhea (IBS-D) significantly impacts health-related quality of life (HRQOL). This post hoc analysis of two phase III trials evaluated the effects of eluxadoline treatment on disease-specific HRQOL among patients with IBS-D.
Adult patients meeting Rome III criteria for IBS-D were randomized to oral eluxadoline (75 mg or 100 mg) or placebo twice daily in two phase III clinical trials for 52 weeks (IBS-3001) and 26 weeks (IBS-3002). The Irritable Bowel Syndrome Quality of Life (IBS-QOL) questionnaire assessed disease-specific HRQOL throughout the study. Changes from baseline to Week 26 in IBS-QOL total and subscale scores were analyzed using an analysis of covariance model. Percentages of IBS-QOL responders with ≥ 14- and 20-point changes were evaluated for IBS-QOL total and subscale scores. A longitudinal mixed-effects model was fitted to evaluate mean IBS-QOL total scores. A cumulative distribution function for change from baseline to Week 26 in IBS-QOL total score was plotted.
Mean changes from baseline to Week 26 for the IBS-QOL total and all subscale scores were significantly higher for patients treated with eluxadoline (both doses) compared to placebo. A significantly greater proportion of eluxadoline-treated patients were responders compared to placebo. Mean and mixed-effects model estimated mean IBS-QOL total scores were consistently higher for eluxadoline versus placebo over 52 weeks.
Compared to placebo, twice-daily eluxadoline treatment significantly improved HRQOL among patients with IBS-D in two phase III trials.
Chey, W. D., Kurlander, J., & Eswaran, S. (2015). Irritable bowel syndrome: A clinical review. Journal of the American Medical Association, 313(9), 949–958. CrossRef
Lacy, B. E., Mearin, F., Chang, L., Chey, W. D., Lembo, A. J., Simren, M., & Spiller, R. (2016). Bowel disorders. Gastroenterology, 150(6), 1393–1407. CrossRef
Canavan, C., West, J., & Card, T. (2014). The epidemiology of irritable bowel syndrome. Clinical Epidemiology, 6, 71–80.
Lovell, R. M., & Ford, A. C. (2012). Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis. Clinical Gastroenterology and Hepatology, 10(7), 712–721. CrossRef
Su, A. M., Shih, W., Presson, A. P., & Chang, L. (2014). Characterization of symptoms in irritable bowel syndrome with mixed bowel habit pattern. Neurogastroenterology and Motility, 26(1), 36–45. CrossRef
Spiller, R., Aziz, Q., Creed, F., Emmanuel, A., Houghton, L., Hungin, P., Jones, R., Kumar, D., Rubin, G., Trudgill, N., & Whorwell, P. (2007). Guidelines on the irritable bowel syndrome: Mechanisms and practical management. Gut, 56(12), 1770–1798. CrossRef
American Gastroenterological Association. (2015). IBS in America: Survey summary findings. Retrieved November 05, 2016, from http://www.multivu.com/players/English/7634451-aga-ibs-in-america-survey/docs/survey-findings-pdf-635473172.pdf.
Buono, J. L., Carson, R. T., & Flores, N. M. (2017). Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea. Health and Quality of Life Outcomes, 15(1), 35. CrossRef
Singh, P., Staller, K., Barshop, K., Dai, E., Newman, J., Yoon, S., Castel, S., & Kuo, B. (2015). Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation. World Journal of Gastroenterology, 21(26), 8103–8109. CrossRef
European Medicines Agency. (2016). Truberzi (eluxadoline) EPAR summary for the public. Retrieved February 14, 2018, from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/004098/WC500213371.pdf.
Wade, P. R., Palmer, J. M., McKenney, S., Kenigs, V., Chevalier, K., Moore, B. A., Mabus, J. R., Saunders, P. R., Wallace, N. H., Schneider, C. R., Kimball, E. S., Breslin, H. J., He, W., & Hornby, P. J. (2012). Modulation of gastrointestinal function by MuDelta, a mixed µ opioid receptor agonist/µ opioid receptor antagonist. British Journal of Pharmacology, 167(5), 1111–1125. CrossRef
US Food and Drug Administration. (2015). Viberzi (eluxadoline) highlights of prescribing information. Retrieved February 14, 2018, from http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206940s000lbl.pdf.
Lembo, A. J., Lacy, B. E., Zuckerman, M. J., Schey, R., Dove, L. S., Andrae, D. A., Davenport, J. M., McIntyre, G., Lopez, R., Turner, L., & Covington, P. S. (2016). Eluxadoline for irritable bowel syndrome with diarrhea. New England Journal of Medicine, 374(3), 242–253. CrossRef
Chey, W. D., Dove, L. S., Andrae, D. A., & Covington, P. S. (2017). Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two phase 3 studies. Alimentary Pharmacology and Therapeutics, 45(10), 1319–1328. CrossRef
Cash, B. D., Lacy, B. E., Schoenfeld, P. S., Dove, L. S., & Covington, P. S. (2017). Safety of eluxadoline in patients with irritable bowel syndrome with diarrhea. American Journal of Gastroenterology, 112(2), 365–374. CrossRef
Chang, L. (2004). Review article: Epidemiology and quality of life in functional gastrointestinal disorders. Alimentary Pharmacology and Therapeutics, 20(Suppl 7), 31–39. CrossRef
Drossman, D. A. (2006). The functional gastrointestinal disorders and the Rome III process. Gastroenterology, 130(5), 1377–1390. CrossRef
Patrick, D. L., Drossman, D. A., Frederick, I. O., DiCesare, J., & Puder, K. L. (1998). Quality of life in persons with irritable bowel syndrome: Development and validation of a new measure. Digestive Diseases and Sciences, 43(2), 400–411. CrossRef
Andrae, D. A., Patrick, D. L., Drossman, D. A., & Covington, P. S. (2013). Evaluation of the Irritable Bowel Syndrome Quality of Life (IBS-QOL) questionnaire in diarrheal-predominant irritable bowel syndrome patients. Health and Quality of Life Outcomes, 11, 208. CrossRef
Andrae, D. A., Covington, P. S., & Patrick, D. L. (2014). Item-level assessment of the irritable bowel syndrome quality of life questionnaire in patients with diarrheal irritable bowel syndrome. Clinical Therapeutics, 36(5), 663–679. CrossRef
Drossman, D., Morris, C. B., Hu, Y., Toner, B. B., Diamant, N., Whitehead, W. E., Dalton, C. B., Leserman, J., Patrick, D. L., & Bangdiwala, S. I. (2007). Characterization of health related quality of life (HRQOL) for patients with functional bowel disorder (FBD) and its response to treatment. American Journal of Gastroenterology, 102(7), 1442–1453. CrossRef
Molenberghs, G., & Kenward, M. G. (2007). Missing data in clinical studies. Chichester: Wiley. CrossRef
El-Serag, H. B., Olden, K., & Bjorkman, D. (2002). Health-related quality of life among persons with irritable bowel syndrome: A systematic review. Alimentary Pharmacology and Therapeutics, 16(6), 1171–1185. CrossRef
Frank, L., Kleinman, L., Rentz, A., Ciesla, G., Kim, J. J., & Zacker, C. (2002). Health-related quality of life associated with irritable bowel syndrome: Comparison with other chronic diseases. Clinical Therapeutics, 24(4), 675–689. CrossRef
- The impact of treatment with eluxadoline on health-related quality of life among adult patients with irritable bowel syndrome with diarrhea
Jessica L. Abel
Robyn T. Carson
David A. Andrae
- Springer International Publishing